18F-FDG-uptake of hepatocellular carcinoma on PET predicts microvascular tumor invasion in liver transplant patients

American Journal of Transplantation

Volumn 9, Issue 3, 2009, Pages 592-600

  Kornberg, A ^a   Freesmeyer, M ^a   Barthel E ^a   Jandt, K ^a   Katenkamp, K ^a   Steenbeck, J ^a   Sappler, A ^a   Habrecht, O ^a   Gottschild, D ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Hepatocellular carcinoma; Liver transplantation; Microvascular invasion; Milan criteria; Positron emission tomography; Tumor biology

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; FLUORODEOXYGLUCOSE F 18; INTERLEUKIN 2 RECEPTOR ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY; DIAGNOSTIC AGENT;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER RECURRENCE; CANCER SCINTISCANNING; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL ARTICLE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER GRAFT REJECTION; LIVER SCINTISCANNING; LIVER TRANSPLANTATION; MALE; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE COMPLICATION; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RADIOISOTOPE DISTRIBUTION; ADOLESCENT; LIVER TUMOR; MIDDLE AGED; PATHOLOGY; RECURRENT DISEASE; SURVIVAL RATE; VASCULARIZATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; POSITRON-EMISSION TOMOGRAPHY; RECURRENCE; SURVIVAL RATE;

EID: 60649084808     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2008.02516.x     Document Type: Article

References (56)

1. Ishizaki Y, Kawasaki S. The evolution of liver transplantation for hepatocellular carcinoma (past, present, and future). J Gastroenterol 2008 43 : 18 26.
2. Iwatsuki S, Gordon RD, Shaw BW Jr., Starzl TE. Role of liver transplantation in cancer therapy. Ann Surg 1985 202 : 401 407.
3. O'Grady JG, Polson RJ, Rolles K, Calne RY, Williams R. Liver transplantation for malignant disease. Results in 93 consecutive patients. Ann Surg 1988 207 : 373 379.
4. Olthoff KM, Millis JM, Rosove MH, Goldstein LI, Ramming KP, Busuttil RW. Is liver transplantation justified for the treatment of hepatic malignancies Arch Surg 1990 125 : 1261 1266.
5. Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996 334 : 693 699.
6. Llovet JM, Bruix J, Fuster J et al. Liver transplantation for small hepatocellular carcinoma: The tumor-node-metastasis classification does not have prognostic power. Hepatology 1998 27 : 1572 1577.
7. Roayaie S, Frischer JS, Emre SH et al. Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann Surg 2002 235 : 533 539.
8. Salizzoni M, Zamboni F, Lupo F, Franchello A, David E, Rizzetto M. Liver transplantation for early-detected, multifocal hepatocellular carcinoma. Br J Surg 2001 88 : 1194 1195.
9. Iwatsuki S, Dvorchik I, Marsh JW et al. Liver transplantation for hepatocellular carcinoma: A proposal of a prognostic scoring system. J Am Coll Surg 2000 191 : 389 394.
10. Marsh JW, Dvorchik I, Bonham CA, Iwatsuki S. Is the pathologic TNM staging system for patients with hepatoma predictive of outcome Cancer 2000 88 : 538 543.
11. Klintmalm GB. Liver transplantation for hepatocellular carcinoma: A registry report of the impact of tumor characteristics on outcome. Ann Surg 1998 228 : 479 490.
12. Jonas S, Bechstein WO, Steinmüller T et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001 33 : 1080 1086.
13. Yao FY, Ferrell L, Bass NM et al. Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival. Hepatology 2001 33 : 1394 1403.
14. Esnaola NF, Lauwers GY, Mirza NQ, et al. Predictors of microvascular invasion in patients with hepatocellular carcinoma who are candidates for orthotopic liver transplantation. J Gastrointest Surg 2002 6 : 224 232.
15. Shah SA, Tan JC, McGilvray ID et al. Does microvascular invasion affect outcomes after liver transplantation for HCC A histopathological analysis of 155 consecutive explants. J Gastrointest Surg 2007 11 : 464 471.
16. Tamura S, Kato T, Berho M et al. Impact of histological grade of hepatocellular carcinoma on the outcome of liver transplantation. Arch Surg 2001 136 : 25 30.
17. Cillo U, Vitale A, Navaglia F, et al. Role of blood AFP mRNA and tumor grade in the preoperative prognostic evaluation of patients with hepatocellular carcinoma. World J Gastroenterol 2005 11 : 6920 6925.
18. Cillo U, Vitale A, Bassanello M et al. Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma. Ann Surg 2004 239 : 150 159.
19. Pawlik TM, Delman KA, Vauthey JN et al. Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl 2005 11 : 1086 1092.
20. Löhe F, Angele MK, Gerbes AL, Löhrs U, Jauch KW, Schauer RJ. Tumour size is an important predictor for the outcome after liver transplantation for hepatocellular carcinoma. Eur J Surg Oncol 2005 31 : 994 999.
21. Sumie S, Kuromatsu R, Okuda K et al. Microvascular invasion in patients with hepatocellular carcinoma and its predictable clinicopathological factors. Ann Surg Oncol 2008 15 : 1375 1382.
22. Parfitt JR, Marotta P, Alghamdi M et al. Recurrent hepatocellular carcinoma after transplantation: Use of a pathological score on explanted livers to predict recurrence. Liver Transpl 2007 13 : 543 542.
23. Teefey SA, Hildeboldt CC, Dehdashti F et al. Detection of primary hepatic malignancy in liver transplant candidates: Prospective comparison of CT, MR imaging, US, and PET. Radiology 2003 226 : 533 542.
24. Delbeke D, Martin WH. Positron emission tomography imaging in oncology. Radiol Clin North Am 2001 39 : 883 917.
25. Jerusalem G, Hustinx R, Beguin Y, Fillet G. The value of positron emission tomography (PET) imaging in disease staging and therapy assessment. Ann Oncol 2002 13 : 227 234.
26. Okazumi S, Isono K, Enomoto K et al. Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose PET: Characterization of tumor and assessment of effect of treatment. J Nucl Med 1992 33 : 333 339.
27. Rigo P, Paulus P, Kaschten BJ et al. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med 1996 23 : 1641 1674.
28. Hatano E, Ikai I, Higashi T et al. Preoperative positron emission tomography with fluorine-18-fluorodeoxyglucose is predictive of prognosis in patients with hepatocellular carcinoma after resection. World J Surg 2006 30 : 1736 1741.
29. Seo S, Hatano E, Higashi T et al. Fluorine-18 fluorodeoxyglucose positron emission tomography predicts tumor differentiation, P-glycoprotein expression, and outcome after resection in hepatocellular carcinoma. Clin Cancer Res 2007 13 : 427 433.
30. Georgiades CS, Hong K, Geschwind JF. Radiofrequency ablation and chemoembolization for hepatocellular carcinoma. Cancer J 2008 14 : 117 122.
31. Yao FY, Hirose R, LaBerge JM et al. A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation. Liver Transpl 2005 11 : 1505 1514.
32. Otto G, Herber S, Heise M et al. Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl 2006 12 : 1260 1267.
33. Böhm B, Voth M, Geoghegan J et al. Impact of positron emission tomography on strategy in liver resection for primary and secondary liver tumors. J Cancer Res Clin Oncol 2004 130 : 266 272.
34. Edmondson Ha, Steiner Pe. Primary carcinoma of the liver: A study of 100 cases among 48,900 necropsies. Cancer 1954 7 : 462 503.
35. Vauthey JN, Lauwers GY, Esnaola NF et al. Simplified staging for hepatocellular carcinoma. J Clin Oncol 2002 20 : 1527 1536.
36. Sobin LH, Wittekind C eds). TNM Classification of Malignant Tumors, 5th ed. New York : Wiley, 1997.
37. Soejima Y, Taketomi A, Yoshizumi T et al. Extended indication for living donor liver transplantation in patients with hepatocellular carcinoma. Transplantation 2007 83 : 893 899.
38. Woo HY, Jang JW, Choi JY et al. Living donor liver transplantation in hepatocellular carcinoma beyond the Milan criteria. Liver Int 2008 28 : 1120 1128.
39. Schwartz ME, D'Amico F, Vitale A, Emre S, Cillo U. Liver transplantation for hepatocellular carcinoma: Are the Milan criteria still valid Eur J Surg Oncol 2008 34 : 256 262.
40. Mazzaferro V, Chun YS, Poon RT et al. Liver transplantation for hepatocellular carcinoma. Ann Surg Oncol 2008 15 : 1001 1007.
41. Kar S, Carr BI. Detection of liver cells in peripheral blood of patients with advanced-stage hepatocellular carcinoma. Hepatology 1995 21 : 403 407.
42. Kienle P, Weitz J, Klaes R et al. Detection of isolated disseminated tumor cells in bone marrow and blood samples of patients with hepatocellular carcinoma. Arch Surg 2000 135 : 213 218.
43. Kornberg A, Kuepper B, Bärthel E, Thrum K, Wilberg J, Settmacher U. Parameters of tumor biology and not Milan criteria alone determine long-term survival after liver transplantation for HCC. Transplant Int 2007 Suppl 2 4.
44. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999 19 : 329 338.
45. Iwatsuki S, Dvorchik I, Marsh JW, et al. Liver transplantation for hepatocellular carcinoma: A proposal of a prognostic scoring system. J Am Coll Surg 2000 191 : 389 394.
46. Pawlik TM, Gleisner AL, Anders RA, Assumpcao L, Maley W, Choti MA. Preoperative assessment of hepatocellular carcinoma tumor grade using needle biopsy: Implications for transplant eligibility. Ann Surg. 2007 245 : 435 442.
47. Perkins JD. Seeding risk following percutaneous approach to hepatocellular carcinoma. Liver Transpl 2007 13 : 1603.
48. Khan MA, Combs CS, Brunt EM et al. Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol 2000 32 : 792 797.
49. Iwata Y, Shiomi S, Sasaki N et al. Clinical usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose in the diagnosis of liver tumors. Ann Nucl Med 2000 14 : 121 126.
50. Yang SH, Suh KS, Lee H et al. The role of (18)F-FDG-PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients. Liver Transpl 2006 12 : 1655 1660.
51. Lee JD, Yun M, Lee JM et al. Analysis of gene expression profiles of hepatocellular carcinomas with regard to 18F-fluorodeoxyglucose uptake pattern on positron emission tomography. Eur J Nucl Med Mol Imaging 2004 31 : 1621 1630.
52. Kirimlioglu H, Dvorchick I, Ruppert K et al. Hepatocellular carcinomas in native livers from patients treated with orthotopic liver transplantation: Biologic and therapeutic implications. Hepatology 2001 34 : 502 510.
53. Zavaglia C, De Carlis L, Alberti AB et al. Predictors of long-term survival after liver transplantation for hepatocellular carcinoma. Am J Gastroenterol 2005 100 : 2708 2716.
54. Yao FY, Bass NM, Nikolai B et al. Liver transplantation for hepatocellular carcinoma: Analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transpl 2002 8 : 873 883.
55. Shah SA, Tan JC, McGilvray ID et al. Accuracy of staging as a predictor for recurrence after liver transplantation for hepatocellular carcinoma. Transplantation 2006 81 : 1633 1639.
56. Torizuka T, Tamaki N, Inokuma T et al. Value of fluorine-18-FDG-PET to monitor hepatocellular carcinoma after interventional therapy. J Nucl Med. 1994 35 : 1965 1969.